Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.

Centella asiatica extract may help promote hair growth by blocking a specific cell signaling pathway.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Gefitinib can cause rare scarring hair loss.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Avacopan may cause unexpected side effects, so early monitoring is important.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Deucravacitinib helped a man regrow hair and improve psoriasis.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

DPCP may be safe for treating alopecia during pregnancy, but more research is needed.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

JAK inhibitors may help treat alopecia areata in children, but their safety needs careful evaluation.

Treprostinil, a drug, can delay wound healing in healthy cells but doesn't affect diabetic foot ulcer cells, suggesting further research could help understand its role in treating these ulcers.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.